Shares of Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) were down 4.7% during mid-day trading on Friday after Royal Bank of Canada lowered their price target on the stock from $29.00 to $27.00. Royal Bank of Canada currently has an outperform rating on the stock. Perspective Therapeutics traded as low as $13.12 and last traded at $13.30. Approximately 417,832 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 603,091 shares. The stock had previously closed at $13.96.
A number of other research firms have also recently weighed in on CATX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a report on Tuesday, June 25th. Bank of America started coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target for the company. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Finally, Oppenheimer cut their price objective on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $19.80.
Insider Activity
In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 3,003 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were purchased at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the completion of the transaction, the director now owns 36,879 shares in the company, valued at $490,490.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Perspective Therapeutics news, CEO Johan M. Spoor bought 10,000 shares of Perspective Therapeutics stock in a transaction on Thursday, June 13th. The stock was purchased at an average cost of $11.70 per share, for a total transaction of $117,000.00. Following the completion of the purchase, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at $160,956.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 3,003 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were acquired at an average price of $13.30 per share, for a total transaction of $39,939.90. Following the purchase, the director now owns 36,879 shares in the company, valued at $490,490.70. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 30,814 shares of company stock worth $385,487. 3.52% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics during the 1st quarter valued at $26,000. Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter worth about $40,000. Bleakley Financial Group LLC acquired a new position in shares of Perspective Therapeutics during the first quarter valued at about $40,000. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics in the second quarter valued at about $117,000. Finally, Point72 DIFC Ltd acquired a new stake in Perspective Therapeutics during the second quarter worth about $118,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.
Perspective Therapeutics Stock Performance
The business’s 50 day moving average price is $11.88. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million for the quarter. On average, equities analysts anticipate that Perspective Therapeutics, Inc. will post -1.02 EPS for the current fiscal year.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.